Cardiovascular Diseases

The recall of Accuretic and generics distributed by Greenstone is a result of the presence of a cancer-causing agent.

But there is no significant difference in rate of hospitalization for major bleeding when Eliquis is compared with Xarelto or warfarin.

Researchers suggest that adjusting the prescribing patterns of about 8% of physicians could result in substantial savings.

The study found that nearly half of Americans diagnosed with high blood pressure do not have it sufficiently controlled.

Across all payers, the use of generic statins has resulted in a savings of $11.9 billion annually.

JAMA Internal Medicine editor and a UCSF colleague wrote in a New England Journ of Medicine opinion piece that the decision highlights the need to establish a new requirement that would make coverage decisions contingent on evidence of benefit for Medicare population.

Besremi is the first interferon approved to treat a disease that causes the overproduction of red blood cells.

If approved, Jardiance would be the first treatment for adults across the full spectrum of heart failure regardless of ejection fraction.

Interviews with 32 patients shows a wide range of experiences but authors say one takeaway is a need for better coordination between HCM specialist and community cardiologists.

Treating and managing patients with paroxysmal nocturnal hemoglobinuria is expensive and requires constant surveillance by the provider and health plan.

Investigators found only small differences in the change in LDL-C levels in the incentive groups versus the control group

Gavreto treats patients with advanced lung care and Arcalyst treats patients with recurrent pericarditis.

Repatha is now available for children 10 and older to lower low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia.

Black HCM patients were more likely than White HCM patients to have mid-ventricular obstruction, according to recently reported findings.

Jardiance demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure.

The full results from the Emperor-Preserved trial show Jardiance reduces the risk of hospital and death from heart failure.

Tecentriq loses indication, Xarelto is approved for reduce risks of cardiovascular events, Tibsovo is approved for rare cancer, Skytrofa is a new, once-weekly growth hormone, and supplemental application is filed Orencia graft-versus-host disease.

ICER calculations using real-world data would result in major price cuts of three therapies — Takhzyro, Haegarda, and Cinryze — if they were to meet commonly used cost-effective thresholds.

Preliminary research shows Anplag could be repurposed as a heart failure treatment at a lower cost.

FDA approves Opdivo, Jardiance for new indication, Jemperli gets accelerated approval for solid tumors, and Lilly’s rapid-acting insulin, Lyumjev is approved for administration via an insulin pump.

Positive trial results were reported in The Lancet last year. The FDA is scheduled (the PDUFA date) to make a decision on the application for approval early next year.

Study finds antibiotics, antidepressants, anti-platelets and other drugs contribute to adverse events and mortality.

The findings were similar in people with or without diabetes.

Competition among branded products did not substantially curb annual spending increases.

Angiotensin receptor blockers may be less likely to cause side effects than ACE inhibitors.